Biological E gets nod to conduct late-stage clinical trials of its COVID-19 vaccine

Biological E gets nod to conduct late-stage clinical trials of its COVID-19 vaccine The Phase III clinical study, which is to be conducted in 15 sites across India, will evaluate the Immunogenicity and Safety of Biological E’s SARS-CoV-2 COVID-19 vaccine for protection against COVID-19 disease in about 1,268 healthy subjects in the age range of 18 to 80 years. It is intended to be part of a larger global Phase III study.

from Moneycontrol Business News https://ift.tt/3njGa3e
Posted by: at
Tags:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Start-up Street: Social justice and the start-up ecosystem

Disparities in start-ups are a global phenomenon and affirmative action is needed to ensure an equal opportunities environment for aspiring...